Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
Article 2024 en
Authors
VH
Vânia Hungria
PR
Paweł Robak
MH
Marek Hus
Abstract
1 min read
As compared with DVd therapy, BVd therapy conferred a significant benefit with respect to progression-free survival among patients who had relapsed or refractory multiple myeloma after at least one line of therapy. Most patients had grade 3 or higher adverse events. (Funded by GSK; DREAMM-7 ClinicalTrials.gov number, NCT04246047; EudraCT number, 2018-003993-29.).
Pieter Sonneveld, Meletios A Dimopoulos, Mario Boccadoro, Hang Quach, P. Joy Ho, Meral Beksaç, Cyrille Hulin, Elisabetta Antonioli, Xavier Leleu, Silvia Mangiacavalli, Aurore Perrot, Michèle Cavo, Angelo Belotti, Annemiek Broijl, Francesca Gay, Roberto Mina, Inger S. Nijhof, Niels W.C.J. van de Donk, Eirini Katodritou, Fredrik Schjesvold, Anna Sureda, Laura Rosiñol, Michel Delforge, Wilfried Roeloffzen,
Marcelo Pitombeira de Lacerda, Meletios A Dimopoulos, Luděk Pour, Kihyun Kim, Sergey Voloshin, Hanlon Sia, Esther González, Chang‐Ki Min, Anna Sureda, Ivan Spicka, Paweł Robak, Marek Hus, Vera Zherebtsova, Merit Hanna, Vinay Jadhav, Nicholas Pirooz, Ianire Garrobo-Calleja, Lydia Eccersley, Vânia Hungria, Meral Beksaç
María-Victoria Mateos, Vânia Hungria, Meral Beksaç, Paweł Robak, Kihyun Kım, Sergey Voloshin, Hanlon Sia, Esther González García, Gracia Martínez, Chang‐Ki Min, Marcelo Pitombeira de Lacerda, Anna Sureda Balarí, Ivan Špıčka, Sosana Delimpasi, Marek Hus, Vera Zherebtsova, Christopher Wård, Phoebe Joy Ho, Roman Hájek, Sebastian Grosicki, S. Yousuf Zafar, Al-Ola Abdallah, Jorge Mouro,
Meletios A Dimopoulos, Albert Oriol, Hareth Nahi, Jesús F. San Miguel, Nizar J. Bahlis, Saad Z. Usmani, Neil Rabin, Robert Z. Orlowski, Mieczysław Komarnicki, Kenshi Suzuki, Torben Plesner, Sung‐Soo Yoon, Dina Ben Yehuda, Paul G. Richardson, Hartmut Goldschmidt, Donna Reece, Steen Lisby, Nushmia Z. Khokhar, Lisa O’Rourke, Christopher Chiu, Xiang Qin, Mary Guckert, Tahamtan Ahmadi, Philippe Moreau
Discussion(0)
No comments yet. Be the first to comment.